Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
1.
Emerg Infect Dis ; 30(3): 555-559, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38407150

ABSTRACT

A neurocysticercosis-like lesion in an 11-year-old boy in the Netherlands was determined to be caused by the zoonotic Taenia martis tapeworm. Subsequent testing revealed that 15% of wild martens tested in that region were infected with T. martis tapeworms with 100% genetic similarity; thus, the infection source was most likely local.


Subject(s)
Neurocysticercosis , Taenia , Male , Child , Animals , Humans , Neurocysticercosis/diagnostic imaging , Taenia/genetics , Netherlands
2.
Eur J Paediatr Neurol ; 41: 91-98, 2022 Nov.
Article in English | MEDLINE | ID: mdl-36410285

ABSTRACT

Vici syndrome (OMIM 242840) is a very rare autosomal recessive multisystem disorder first described in 1988. In 2013, bi-allelic loss-of-function mutations in EPG5 were reported to cause Vici syndrome. Five principal diagnostic features of Vici syndrome have been proposed: agenesis of the corpus callosum, cataracts, cardiomyopathy, hypopigmentation, and combined immunodeficiency. We identified 15 patients carrying a homozygous founder missense variant in EPG5 who all exhibit a less severe clinical phenotype than classic Vici syndrome. All 15 show typical brain abnormalities on MRI. The homozygous founder variant in EPG5 they carry results in a shorter in-frame transcript and truncated, but likely still residual, EPG5 protein. We speculate that the residual EPG5 protein explains their attenuated phenotype, which is consistent with two previous observations that low expression of EPG5 can lead to an attenuated Vici syndrome phenotype. We propose renaming this condition EPG5-related neurodevelopmental disorder to emphasize the clinical variability of patients with bi-allelic mutations in EPG5.


Subject(s)
Cataract , Humans , Cataract/genetics , Phenotype , Homozygote , Corpus Callosum , Autophagy-Related Proteins , Vesicular Transport Proteins/genetics
3.
Clin Genet ; 102(4): 350-351, 2022 10.
Article in English | MEDLINE | ID: mdl-35791803

ABSTRACT

We report a 19-month-old patient with cardiomyopathy as the first presenting feature of primary COQ10 deficiency-6. This case expands the phenotypic spectrum of this disorder. Furthermore, it shows that genetic testing for primary COQ10 deficiency should be considered in patients with pediatric-onset cardiomyopathy as it can guide treatment options.


Subject(s)
Cardiomyopathies , Mitochondrial Diseases , Ataxia/genetics , Cardiomyopathies/diagnosis , Cardiomyopathies/genetics , Humans , Infant , Mitochondrial Diseases/diagnosis , Mitochondrial Diseases/genetics , Muscle Weakness , Mutation , Ubiquinone/deficiency
4.
Eur J Paediatr Neurol ; 25: 172-180, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31753707

ABSTRACT

BACKGROUND: Melatonin may offer a safe and cheap alternative to general anaesthesia and sedatives in neuropaediatric MRI. The purpose of our study was to evaluate its efficacy during a daily scanning programme and to assess its financial benefit. METHODS: Neuro-MRI scans, performed in a general hospital setting after administration of melatonin in 64 children aged 10 months-5 years, were retrospectively reassessed by an experienced paediatric neuroradiologist, rating them as diagnostically contributing or as failed. The financial benefit was calculated. RESULTS: 49/64 scans (77%) were diagnostically contributing, in 11 (22%) no movement artefact was seen in any sequence; 15/64 scans failed (23%), in 3/15 because of serious movement artefacts, in 12/15 the scan was not started. Repeat scans under general anaesthesia were performed in 17 cases (27%): in the 15 failed cases and in 2 cases initially assessed as failed, but were considered diagnostically contributing in the present study. The financial benefit at the time the scans were made was approximately 13,360 Euro. CONCLUSIONS: In this retrospective study, the use of melatonin in neuropaediatric MRI, made during a daily scanning programme with a remote waiting room, was associated with a high success rate in infants and young children. A minority of scans had no movement artefacts, indicating most children were not asleep. The sleep-inducing effect of melatonin could therefore not be proven, but the high success rate may be attributed to the sedative and/or anxiolytic effect of melatonin. Only a minority of scans had to be repeated under general anesthesia, leading to a reduction of scan related costs.


Subject(s)
Hypnotics and Sedatives/therapeutic use , Magnetic Resonance Imaging/methods , Melatonin/therapeutic use , Neuroimaging/methods , Artifacts , Child , Child, Preschool , Female , Hospitals, General , Humans , Infant , Male , Movement , Retrospective Studies
5.
Eur J Pediatr ; 178(9): 1305-1315, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31338675

ABSTRACT

Acute flaccid myelitis is characterized by the combination of acute flaccid paralysis and a spinal cord lesion largely restricted to the gray matter on magnetic resonance imaging. The term acute flaccid myelitis was introduced in 2014 after the upsurge of pediatric cases in the USA with enterovirus D68 infection. Since then, an increasing number of cases have been reported worldwide. Whereas the terminology is new, the clinical syndrome has been recognized in the past in association with several other neurotropic viruses such as poliovirus.Conclusion: This review presents the current knowledge on acute flaccid myelitis with respect to the clinical presentation and its differential diagnosis with Guillain-Barré syndrome and acute transverse myelitis. We also discuss the association with enterovirus D68 and the presumed pathophysiological mechanism of this infection causing anterior horn cell damage. Sharing clinical knowledge and insights from basic research is needed to make progress in diagnosis, treatment, and prevention of this new polio-like disease. What is Known: • Acute flaccid myelitis (AFM) is a polio-like condition characterized by rapid progressive asymmetric weakness, together with specific findings on MRI • AFM has been related to different viral agents, but recent outbreaks are predominantly associated with enterovirus D68. What is New: • Improving knowledge on AFM must increase early recognition and adequate diagnostic procedures by clinicians. • The increasing incidence of AFM urges cooperation between pediatricians, neurologists, and microbiologists for the development of treatment and preventive options.


Subject(s)
Central Nervous System Viral Diseases/diagnosis , Enterovirus D, Human , Enterovirus Infections/diagnosis , Myelitis/diagnosis , Neuromuscular Diseases/diagnosis , Central Nervous System Viral Diseases/epidemiology , Central Nervous System Viral Diseases/therapy , Central Nervous System Viral Diseases/virology , Diagnosis, Differential , Enterovirus Infections/complications , Enterovirus Infections/epidemiology , Enterovirus Infections/therapy , Global Health , Guillain-Barre Syndrome/diagnosis , Guillain-Barre Syndrome/virology , Humans , Myelitis/epidemiology , Myelitis/therapy , Myelitis/virology , Myelitis, Transverse/diagnosis , Myelitis, Transverse/virology , Neuromuscular Diseases/epidemiology , Neuromuscular Diseases/therapy , Neuromuscular Diseases/virology , Prognosis
6.
Eur J Paediatr Neurol ; 22(3): 536-540, 2018 May.
Article in English | MEDLINE | ID: mdl-29274890

ABSTRACT

Molybdenum cofactor deficiency type A (MoCD-A) is an inborn error of metabolism presenting early after birth with severe seizures. Recently, experimental substitution treatment with cyclic pyranopterin monophosphate (cPMP) has become available. Because prenatal data is scarce, we report data of prenatal Magnetic Resonance Imaging (MRI) in two cases with MoCD-A demonstrating signs of possible early brain injury. Prenatal MRI can be used for monitoring in MoCD-A to guide decision-making in timing of delivery.


Subject(s)
Brain/diagnostic imaging , Magnetic Resonance Imaging/methods , Metal Metabolism, Inborn Errors/diagnostic imaging , Prenatal Diagnosis/methods , Brain/pathology , Female , Humans , Metal Metabolism, Inborn Errors/pathology , Pregnancy
7.
J Pediatr ; 192: 33-40.e2, 2018 01.
Article in English | MEDLINE | ID: mdl-29246356

ABSTRACT

OBJECTIVE: To assess the predictive value of a novel magnetic resonance imaging (MRI) score, which includes diffusion-weighted imaging as well as assessment of the deep grey matter, white matter, and cerebellum, for neurodevelopmental outcome at 2 years and school age among term infants with hypoxic-ischemic encephalopathy treated with therapeutic hypothermia. STUDY DESIGN: This retrospective cohort study (cohort 1, The Netherlands 2008-2014; cohort 2, Sweden 2007-2012) including infants born at >36 weeks of gestational age treated with therapeutic hypothermia who had an MRI in the first weeks of life. The MRI score consisted of 3 subscores: deep grey matter, white matter/cortex, and cerebellum. Primary adverse outcome was defined as death, cerebral palsy, Bayley Scales of Infant and Toddler Development, third edition, motor or cognitive composite scores at 2 years of <85, or IQ at school age of <85. RESULTS: In cohort 1 (n = 97) and cohort 2 (n = 76) the grey matter subscore was an independent predictor of adverse outcome at 2 years (cohort 1, OR, 1.6; 95% CI, 1.3-1.9; cohort 2, OR, 1.4; 95% CI, 1.2-1.6), and school age (cohort 1, OR, 1.3; 95% CI, 1.2-1.5; cohort 2, OR, 1.3; 95% CI, 1.1-1.6). The white matter and cerebellum subscore did not add to the predictive value. The positive predictive value, negative predictive value, and area under the curve for the grey matter subscore were all >0.83 in both cohorts, whereas the specificity was >0.91 with variable sensitivity. CONCLUSION: A novel MRI score, which includes diffusion-weighted imaging and assesses all brain areas of importance in infants with therapeutic hypothermia after perinatal asphyxia, has predictive value for outcome at 2 years of age and at school age, for which the grey matter subscore can be used independently.


Subject(s)
Asphyxia Neonatorum/diagnostic imaging , Cerebral Palsy/etiology , Developmental Disabilities/etiology , Diffusion Magnetic Resonance Imaging , Hypothermia, Induced , Hypoxia-Ischemia, Brain/diagnostic imaging , Severity of Illness Index , Asphyxia Neonatorum/complications , Asphyxia Neonatorum/mortality , Asphyxia Neonatorum/therapy , Brain/diagnostic imaging , Cerebral Palsy/diagnosis , Child , Child, Preschool , Decision Support Techniques , Developmental Disabilities/diagnosis , Female , Follow-Up Studies , Humans , Hypoxia-Ischemia, Brain/complications , Hypoxia-Ischemia, Brain/mortality , Hypoxia-Ischemia, Brain/therapy , Infant, Newborn , Logistic Models , Male , Predictive Value of Tests , Retrospective Studies , Treatment Outcome
8.
Am J Med Genet C Semin Med Genet ; 175(4): 450-464, 2017 12.
Article in English | MEDLINE | ID: mdl-29168326

ABSTRACT

"CHARGE syndrome" is a complex syndrome with high and extremely variable comorbidity. As a result, clinicians may struggle to provide accurate and comprehensive care, and this has led to the publication of several clinical surveillance guidelines and recommendations for CHARGE syndrome, based on both single case observations and cohort studies. Here we perform a structured literature review to examine all the existing advice. Our findings provide additional support for the validity of the recently published Trider checklist. We also identified a gap in literature when reviewing all guidelines and recommendations, and we propose a guideline for neuroradiological evaluation of patients with CHARGE syndrome. This is of importance, as patients with CHARGE are at risk for peri-anesthetic complications, making recurrent imaging procedures under anesthesia a particular risk in clinical practice. However, comprehensive cranial imaging is also of tremendous value for timely diagnosis, proper treatment of symptoms and for further research into CHARGE syndrome. We hope the guideline for neuroradiological evaluation will help clinicians provide efficient and comprehensive care for individuals with CHARGE syndrome.


Subject(s)
CHARGE Syndrome/diagnosis , CHARGE Syndrome/therapy , Brain/abnormalities , CHARGE Syndrome/genetics , Disease Management , Humans , Neuroimaging/methods , Practice Guidelines as Topic
9.
Neuropsychologia ; 103: 131-139, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28723344

ABSTRACT

Behavioural disturbances are frequently found after aneurysmal subarachnoid haemorrhage (aSAH). Social cognition impairments have been suggested as a possible underlying mechanism for behavioural problems. Also, aSAH is likely to result in damage affecting frontal-subcortical circuits underlying social cognition. Therefore, we aimed to investigate social cognition after aSAH and its associations with behavioural problems (deficits in interpersonal behaviour, apathy, and impaired self-awareness) and focal as well as diffuse brain damage. 88 aSAH patients (in the subacute phase post-aSAH) and 60 age-, sex- and education-matched healthy controls participated. Tasks for emotion recognition, Theory of Mind (ToM), and empathy as well as questionnaires were used. Cortical infarctions in frontal and non-frontal areas on MRI, aneurysm circulation and aSAH-related events were taken into account. Compared to healthy controls, aSAH patients performed significantly worse on tasks for emotion recognition, ToM and empathy. Poor performance on ToM and emotion recognition was associated with proxy-ratings indicating impaired interpersonal behaviour and apathy and with indications of impaired self-awareness. No associations were found between deficits in social cognition and frontal or non-frontal cortical lesions on MRI. Also, aneurysm circulation and aSAH-related events such as hydrocephalus, vasospasm, and treatment method did not explain why and how social cognitive deficits did occur after aSAH. In conclusion, emotion recognition, ToM and empathy were clearly impaired in aSAH patients and these deficits were related to apathy and deficits in interpersonal behaviour as reported by proxies and to impaired self-awareness. This association strengthens the assumption of impaired social cognition as an underlying construct of behavioural problems after aSAH. Consequently, social cognition tests and proxy-ratings should be used in clinical practice, irrespective of lesion location on MRI or aneurysm circulation, to improve the detection and treatment of apathy and deficits in interpersonal behaviour after aSAH.


Subject(s)
Apathy , Cognition Disorders/etiology , Empathy , Self Concept , Social Perception , Subarachnoid Hemorrhage/psychology , Angiography, Digital Subtraction , Cerebral Angiography , Cognition Disorders/diagnostic imaging , Computed Tomography Angiography , Emotional Intelligence , Facial Recognition , Female , Humans , Interpersonal Relations , Male , Middle Aged , Neuropsychological Tests , Subarachnoid Hemorrhage/complications , Subarachnoid Hemorrhage/diagnostic imaging , Theory of Mind , Tomography, X-Ray Computed
12.
World Neurosurg ; 93: 410-2, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27368505

ABSTRACT

BACKGROUND: In deep brain stimulation (DBS), accurate placement of the lead is critical. Target definition is highly dependent on visual recognition on magnetic resonance imaging (MRI). We prospectively investigated whether the 7-T MRI enabled better visualization of targets and led to better placement of leads compared with the 1.5-T and the 3-T MRI. METHODS: Three patients with PD (mean, 55 years) were scanned on 1.5-, 3-, and 7-T MRI before surgery. Tissue contrast and signal-to-noise ratio were measured. Target coordinates were noted on MRI and during surgery. Differences were analyzed with post-hoc analysis of variance. RESULTS: The 7-T MRI demonstrated a significant improvement in tissue visualization (P < 0.005) and signal-to-noise ratio (P < 0.005). However, no difference in the target coordinates was found between the 7-T and the 3-T MRI. CONCLUSIONS: Although the 7-T MRI enables a significant better visualization of the DBS target in patients with PD, we found no clinical benefit for the placement of the DBS leads.


Subject(s)
Deep Brain Stimulation/instrumentation , Deep Brain Stimulation/methods , Magnetic Resonance Imaging/methods , Parkinson Disease/prevention & control , Parkinson Disease/surgery , Prosthesis Implantation/methods , Electrodes, Implanted , Humans , Parkinson Disease/diagnostic imaging , Reproducibility of Results , Sensitivity and Specificity , Surgery, Computer-Assisted/methods , Treatment Outcome
13.
Radiother Oncol ; 114(2): 239-44, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25596913

ABSTRACT

BACKGROUND AND PURPOSE: To assess and compare brain abnormalities on Magnetic Resonance Imaging (MRI) in non-functioning pituitary macro-adenoma (NFA) patients treated with or without postoperative radiotherapy (RT). MATERIAL AND METHODS: In 86 NFA patients, treated between 1987 and 2008 at the University Medical Center Groningen, white-matter lesions (WMLs), cerebral atrophy, brain infarctions and abnormalities of the temporal lobes and hippocampi were assessed on pre- and post-treatment MRI scans in patients treated with (n=47) or without RT. RESULTS: The median MRI follow-up time for RT patients was 10 (range 1-22) years and 5 (range 1-21) years in patients treated without RT. In RT patients the cumulative incidence of WMLs was significantly lower compared to patients treated without RT (log-rank test RR 0.49, 95% CI 0.25-0.97, p=.042). The cumulative incidences of cerebral atrophy, brain infarctions, abnormalities of the temporal lobes and hippocampi, and the severity of WMLs and cerebral atrophy ratings were not significantly different between the two treatment groups. CONCLUSIONS: Brain abnormalities on MRI are not observed more frequently in NFA patients treated with RT compared to patients treated with surgery-alone. Furthermore, RT was not associated with an increased severity of WMLs and cerebral atrophy ratings in this cohort of NFA patients.


Subject(s)
Adenoma/radiotherapy , Brain Diseases/diagnosis , Brain Diseases/etiology , Pituitary Neoplasms/radiotherapy , Adenoma/pathology , Adenoma/surgery , Adult , Aged , Atrophy , Brain Infarction/diagnosis , Brain Infarction/etiology , Cerebral Cortex/pathology , Cerebral Cortex/radiation effects , Female , Hippocampus/pathology , Hippocampus/radiation effects , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Pituitary Neoplasms/pathology , Pituitary Neoplasms/surgery , Postoperative Period , Radiation Injuries/diagnosis , Radiation Injuries/etiology , Temporal Lobe/pathology , Temporal Lobe/radiation effects , White Matter/pathology , White Matter/radiation effects , Young Adult
14.
Eur J Radiol ; 84(2): 295-300, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25523821

ABSTRACT

PURPOSE: The extent to which cognitive dysfunction is related to specific brain abnormalities in patients treated for pituitary macroadenoma is unclear. Therefore, we compared brain abnormalities seen on Magnetic Resonance Imaging (MRI) in patients treated for nonfunctioning pituitary macroadenoma (NFA) with or without impairments in cognitive functioning. METHODS: In this cross-sectional design, a cohort of 43 NFA patients was studied at the University Medical Center Groningen. White matter lesions (WMLs), cerebral atrophy, (silent) brain infarcts and abnormalities of the temporal lobes and hippocampi were assessed on pre-treatment and post-treatment MRI scans. Post-treatment cognitive examinations were performed using a verbal memory and executive functioning test. We compared our patient cohort with large reference populations representative of the Dutch population. RESULTS: One or more impairments on both cognitive tests were frequently observed in treated NFA patients. No treatment effects were found with regard to the comparison between patients with and without impairments in executive functioning. Interestingly, in patients with one or more impairments on verbal memory function, treatment with radiotherapy had been given more frequently (74% in the impaired group versus 40% in the unimpaired group, P=0.025). Patients with or without any brain abnormality on MRI did not differ in verbal memory or executive functioning. CONCLUSIONS: Brain abnormalities on MRI are not observed more frequently in treated NFA patients with impairments compared to NFA patients without impairments in verbal memory or executive functioning. Conversely, the absence of brain abnormalities on MRI does not exclude impairments in cognition.


Subject(s)
Adenoma/therapy , Brain/pathology , Cognition Disorders/pathology , Magnetic Resonance Imaging , Pituitary Neoplasms/pathology , Pituitary Neoplasms/therapy , Aged , Atrophy/diagnosis , Brain Infarction/diagnosis , Cognition , Cross-Sectional Studies , Female , Follow-Up Studies , Hippocampus/pathology , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Temporal Lobe/pathology
15.
Elife ; 2: e01305, 2013 Dec 24.
Article in English | MEDLINE | ID: mdl-24368733

ABSTRACT

Mutations in CHD7 are the major cause of CHARGE syndrome, an autosomal dominant disorder with an estimated prevalence of 1/15,000. We have little understanding of the disruptions in the developmental programme that underpin brain defects associated with this syndrome. Using mouse models, we show that Chd7 haploinsufficiency results in reduced Fgf8 expression in the isthmus organiser (IsO), an embryonic signalling centre that directs early cerebellar development. Consistent with this observation, Chd7 and Fgf8 loss-of-function alleles interact during cerebellar development. CHD7 associates with Otx2 and Gbx2 regulatory elements and altered expression of these homeobox genes implicates CHD7 in the maintenance of cerebellar identity during embryogenesis. Finally, we report cerebellar vermis hypoplasia in 35% of CHARGE syndrome patients with a proven CHD7 mutation. These observations provide key insights into the molecular aetiology of cerebellar defects in CHARGE syndrome and link reduced FGF signalling to cerebellar vermis hypoplasia in a human syndrome. DOI: http://dx.doi.org/10.7554/eLife.01305.001.


Subject(s)
CHARGE Syndrome/metabolism , Cerebellar Vermis/metabolism , Fibroblast Growth Factor 8/metabolism , Homeodomain Proteins/metabolism , Otx Transcription Factors/metabolism , Animals , CHARGE Syndrome/genetics , CHARGE Syndrome/pathology , Cerebellar Vermis/abnormalities , DNA Helicases/genetics , DNA Helicases/metabolism , DNA-Binding Proteins/deficiency , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Disease Models, Animal , Fibroblast Growth Factor 8/deficiency , Fibroblast Growth Factor 8/genetics , Gene Expression Regulation , Genotype , Haploinsufficiency , Homeodomain Proteins/genetics , Humans , Magnetic Resonance Imaging , Mice, Inbred C57BL , Mice, Inbred DBA , Mice, Knockout , Mutation , Otx Transcription Factors/genetics , Phenotype
16.
Eur Radiol ; 22(4): 772-8, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22057247

ABSTRACT

OBJECTIVE: Magnetic resonance spectroscopy can identify brain metabolic changes in perinatal asphyxia by providing ratios of metabolites, such as choline (Cho), creatine (Cr), N-acetyl aspartate (NAA) and lactate (Lact) [Cho/Cr, Lact/NAA, etc.]. The purpose of this study was to quantify the separate white and grey matter metabolites in a slab cranial to the ventricles and relate these to the outcome. METHODS: A standard 2D-chemical shift imaging protocol was used for measuring a transverse volume of interest located cranial to the ventricles allowing for direct comparison of the metabolites in white and grey matter brain tissue in 24 term asphyxiated newborns aged 3 to 16 days. RESULTS: Cho, NAA and Lact showed significant differences between four subgroups of asphyxiated infants with more and less favourable outcomes. High levels of Cho and Lact in the grey matter differentiated non-survivors from survivors (P = 0.003 and P = 0.017, respectively). CONCLUSION: In perinatal asphyxia the levels of Cho, NAA and Lact in both white and grey matter brain tissue are affected. The levels of Cho and Lact measured in the grey matter are the most indicative of survival. It is therefore advised to include grey matter brain tissue in the region of interest examined by multivoxel MR spectroscopy. KEY POINTS: Magnetic resonance spectroscopy can identify brain metabolic changes in perinatal asphyxia. Choline and lactate levels in grey matter seem the best indicators of survival. Both grey and white matter should be examined during spectroscopy for perinatal asphyxia.


Subject(s)
Asphyxia Neonatorum/metabolism , Asphyxia Neonatorum/mortality , Brain/metabolism , Magnetic Resonance Spectroscopy/methods , Nerve Fibers, Myelinated/metabolism , Neurons/metabolism , Asphyxia Neonatorum/diagnosis , Female , Humans , Imaging, Three-Dimensional/methods , Infant, Newborn , Magnetic Resonance Imaging/methods , Male , Netherlands/epidemiology , Prevalence , Prognosis , Survival Analysis , Survival Rate
17.
Eur J Endocrinol ; 166(2): 171-9, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22071311

ABSTRACT

OBJECTIVE: The hippocampus and prefrontal cortex (PFC) are important for memory and executive functioning and are known to be sensitive to radiotherapy (RT). Radiation dosimetry relates radiation exposure to specific brain areas. The effects of various pituitary RT techniques were studied by relating detailed dosimetry of the hippocampus and PFC to cognitive performance. METHODS: In this cross-sectional design, 75 non-functioning pituitary macroadenoma (NFA) patients (61±10 years) participated and were divided into irradiated (RT+, n=30) and non-irradiated (RT-, n=45) groups. The RT+ group (who all received 25 fractions of 1.8 Gy; total dose: 45 Gy) consisted of three RT technique groups: three-field technique, n=10; four-field technique, n=15; and five-field technique, n=5. Memory and executive functioning were assessed by standardized neuropsychological tests. A reconstruction of the dose distributions for the three RT techniques was made. The RT doses on 30, 50, and 70% of the volume of the left and right hippocampus and PFC were calculated. RESULTS: Cognitive test performance was not different between the four groups, despite differences in radiation doses applied to the hippocampi and PFC. Age at RT, time since RT, and the use of thyroid hormone varied significantly between the groups; however, they were not related to cognitive performance. CONCLUSION: This study showed that there were no significant differences on cognitive performance between the three-, four-, and five-field RT groups and the non-irradiated patient group. A dose-response relationship could not be established, even with a radiation dose that was higher on most of the volume of the hippocampus and PFC in case of a four-field RT technique compared with the three- and five-field RT techniques.


Subject(s)
Adenoma/radiotherapy , Adenoma/surgery , Cognition/physiology , Hippocampus/radiation effects , Pituitary Neoplasms/radiotherapy , Pituitary Neoplasms/surgery , Prefrontal Cortex/radiation effects , Adenoma/physiopathology , Adenoma/psychology , Adolescent , Adult , Aged , Aged, 80 and over , Cognition/radiation effects , Combined Modality Therapy , Cross-Sectional Studies , Female , Hippocampus/physiology , Humans , Male , Middle Aged , Neuropsychological Tests , Pituitary Neoplasms/physiopathology , Pituitary Neoplasms/psychology , Prefrontal Cortex/physiology , Radiometry , Radiotherapy Dosage , Task Performance and Analysis , Young Adult
18.
J Pediatr ; 158(3): 474-9, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20884005

ABSTRACT

OBJECTIVE: To test the hypothesis that a smell test could predict the occurrence of hypogonadotropic hypogonadism (HH) in patients with CHARGE syndrome, which is a variable combination of ocular coloboma, heart defects, choanal atresia, retardation of growth/development, genital hypoplasia, and ear anomalies or hearing loss caused by mutations in the CHD7 (chromodomain helicase DNA binding protein 7) gene. STUDY DESIGN: We performed endocrine studies and smell testing (University of Pennsylvania Smell Identification Test) in 35 adolescent patients with molecularly confirmed CHARGE syndrome. RESULTS: Complete data on smell and puberty were available for 15 patients; 11 patients had both anosmia and HH, whereas 4 patients had normosmia/hyposmia and spontaneous puberty. In addition, 7 boys were highly suspected of having HH (they were too young for definite HH diagnosis, but all had cryptorchidism, micropenis, or both) and had anosmia. The type of CHD7 mutation could not predict HH because a father and daughter with the same CHD7 mutation were discordant for HH and anosmia. CONCLUSION: Anosmia and HH were highly correlated in our cohort, and therefore smell testing seems to be an attractive method for predicting the occurrence of HH in patients with CHARGE syndrome. The use of this test could prevent delay of hormonal pubertal induction, resulting in an age-appropriate puberty.


Subject(s)
CHARGE Syndrome , Hypogonadism/diagnosis , Olfaction Disorders/diagnosis , Puberty, Delayed/prevention & control , Adolescent , Adult , Child , Female , Hormone Replacement Therapy , Humans , Hypogonadism/complications , Magnetic Resonance Imaging , Male , Netherlands , Olfaction Disorders/etiology , Olfactory Bulb/pathology , Predictive Value of Tests
19.
Eur J Med Genet ; 53(5): 344-6, 2010.
Article in English | MEDLINE | ID: mdl-20553986

ABSTRACT

Polymicrogyria (PMG) is a brain malformation due to abnormal cortical organisation. It is a heterogeneous disorder associated with 22q11.2 deletion syndrome (also known as velocardiofacial (VCF) syndrome) amongst others. Since this association was first recognised in 1996, over 30 patients with PMG and 22q11.2 deletion have been described. In 22q11.2 deletion syndrome, PMG is mainly located in the perisylvian areas; it frequently has an asymmetrical presentation with a striking predisposition for the right hemisphere. Neurological features of perisylvian PMG include developmental delay/mental retardation, seizures, microcephaly, spasticity and oromotor dysfunction. Thus in children diagnosed with 22q11.2 deletion syndrome, a finding of PMG has important prognostic value. We present a seven-month old boy with microcephaly, short stature and developmental delay. A cerebral MRI showed slightly enlarged ventricles and symmetrical perisylvian polymicrogyria. A 22q11.2 deletion was revealed by array-based comparative genomic hybridization. Remarkably the boy had no other manifestations of VCF syndrome. Paediatricians, child neurologists and clinical geneticists should be aware that the presence of PMG (especially in the perisylvian areas) needs investigating for 22q11.2 deletion, even if other more common VCF syndrome features are absent.


Subject(s)
Chromosome Deletion , Chromosomes, Human, Pair 22 , Malformations of Cortical Development/genetics , Cerebral Cortex/abnormalities , Developmental Disabilities/genetics , DiGeorge Syndrome/genetics , Humans , Infant , Intellectual Disability/genetics , Magnetic Resonance Imaging , Male , Microcephaly/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...